High grade evidence that we can screen with PSA and mitigate over diagnosis of low grade disease with MRI (and of course help reduce over treatment). The case for a screening programme grows daily stronger.

Dr. Karen Fransis is one of the most experienced urologists teaching the 𝗿𝗲𝘁𝘇𝗶𝘂𝘀-𝘀𝗽𝗮𝗿𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗶𝗾𝘂𝗲 for #RadicalProstatectomy. For the training of Dr. Martinez, she implemented a very innovative approach 🧵👇🏼

Alle middelen zijn goed om de laatste ondernemers en risiconemers in België weg te jagen. We creëren alleen nog overheidsjobs maar dat levert meer stemmen op.

⚡️Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection #BladderCancer European Urology europeanurology.com/article/S0302-…

A brilliant editorial! PSA dynamics remain a vital, cost-effective tool for guiding treatments, complemented by cutting-edge genomics and imaging. #prostatecancer #Cancer @chadihc98 Zeynep Irem Ozay, MD Neeraj Agarwal, MD, FASCO Umang Swami, MD, MSCI, FASCO European Urology OncoAlert Advanced Prostate Cancer Consensus Conference

Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study by Daimantas Milonas et al buff.ly/3BqRqWM #UroSoMe #MedTwitter #EUO #PCa #ProstateCancer

Feeling truly proud today. Just yesterday we were talking about how important it is to see ourselves reflected on stage and in the OR—and today, watching @albasierraD, who was once my resident, perform live surgery at #EAU25, is both powerful and deeply moving. Female surgeons

Female urologists I admire — you are true role models. I hope to be like you one day! So proud! MMusquera Maria J. Ribal Silvia Secco Karen Fransis Surgery in the 3rd millennium:skills beyond gender #UroFem

ctDNA can help guide adjuvant decision making in MIBC In pts with undetectable ctDNA after NAC + cystectomy, no definitive benefit for adjuvant ICB authors.elsevier.com/c/1lMET14kpm0h… Matt Galsky The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Uromigos Bladder Cancer Advocacy Network UroToday.com World Bladder Cancer Patient Coalition OncLive.com

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr OncoAlert Annals of Oncology astrazeneca.com/media-centre/p…